Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.

Academic Article

Abstract

  • BACKGROUND: Epithelial ovarian cancer (EOC) recurrence is common following treatment with cytoreductive surgery and adjuvant chemotherapy. Numerous antineoplastic agents have been utilized for recurrent EOC, with varied response rates and toxicity. Recently the combination of topotecan and thalidomide was shown to be superior to topotecan alone in terms of response and progression-free survival. CASES: Two women with recurrent EOC were treated with weekly topotecan and daily thalidomide. A total of 8 cycles were administered. Grade 3 fatigue occurred in both patients, resulting in a dose reduction of thalidomide, with toxicity otherwise acceptable. One patient had a partial response, while the second patient had stable disease. Therapy was ultimately discontinued for progressive disease in both patients. CONCLUSION: Our report describes a well-tolerated, novel use of a weekly topotecan and daily thalidomide regimen. This regimen may be a reasonable alternative to the standard regimen of day 1-5 topotecan and thalidomide and should be further evaluated.
  • Keywords

  • Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Drug Administration Schedule, Fatigue, Female, Humans, Immunosuppressive Agents, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Thalidomide, Topotecan
  • Author List

  • Phippen NT; Leath CA
  • Start Page

  • 583
  • End Page

  • 586
  • Volume

  • 54
  • Issue

  • 9